Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 332

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 332
---
 
     1,817,017  
     18,170  
     1,750,304  
     -  
     -  
     1,768,474 
  
    Net loss 
     -  
     -  
     -  
     (15,022,027) 
     -  
     (15,022,027)
  
    Balance, December 31, 2024 
     12,013,901  
    $120,139  
    $64,263,919  
    $(60,439,183) 
    $-  
    $3,944,875 
  
    Balance 
     12,013,901  
    $120,139  
    $64,263,919  
    $(60,439,183) 
    $-  
    $3,944,875 

See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

F-5

INDAPTUS
THERAPEUTICS, INC.

Consolidated
Statements of Cash Flows

    2024  
     2023 

    For the year ended December 31, 

    2024  
     2023 
  
    Cash flows from operating activities: 

    Net loss 
    $(15,022,027) 
    $(15,423,471)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     735  
     1,284 
  
    Stock-based compensation 
     2,305,849  
     2,965,938 
  
    Interest earned on marketable securities 
     -  
     (430,993)
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current and non-current assets 
     (81,944) 
     161,800 
  
    Accounts payable and other current liabilities 
     474,057  
     (680,520)
  
    Operating lease right-of-use asset and liability, net 
     142  
     647 
  
    Net cash used in operating activities 
     (12,323,188) 
     (13,405,315)

    Cash flows from investing activities: 

    Purchase of marketable